Skip to content

Information and Resources

Cheap, Generic 'Biologics' on the Way?

Congress Considers Allowing Companies to Make Low-Cost Copies of Drugs Like Insulin
Font Size
A
A
A

Complex Copying

Generic drugs can cost half of their identical brand-name "parents," and insurers, employers, and patients credit them with savings billions in health costs each year. The copies are made by mimicking chemical active ingredients in a laboratory.

But biologics contain active molecules far larger and more complex than those in existing generics. Those molecules can’t be precisely copied synthetically, and brand-name drugmakers closely guard information about the delicate and complicated biological reactions needed to produce them biologically.

Brand-name drugmakers maintain that the uncertainty makes generic biologics inherently unreliable and potentially unsafe. They want Congress to bar biologic generics from FDA rules that let drug companies make them without putting them through expensive human clinical studies.

"[Generic] biologics can be shown to be similar, but never identical, to an innovator," said Jay P. Siegel, MD, president of biotechnology, immunology, and oncology research and development at Johnson & Johnson, one of the world’s largest manufacturers of biologics.

"You can’t just take a molecule that has never been in people ... then all of the sudden market it to thousands of people. It’s too risky," he said.

Generic Companies: We Can Do It

Generic manufacturers, meanwhile, say technology now allows them to backtrack from a biologic’s ingredients and closely approximate its molecular structure. They accuse brand-name companies of stonewalling for fear of losing billions in revenues.

"The science is here and has been for over a decade," said Ajaz S. Hussain, vice president for biopharmaceutical development at Sandoz, a generic company owned by Novartis.

Complex as a 'Skyscraper'

A bill introduced last month would give the FDA the power for fast-track approval of generic biologics on a case-by-case basis, as long as companies can show they are essentially equivalent to the brand-name parent.

"The science supports an abbreviated pathway for [generic] biologics," said Sen. Hillary Rodham Clinton, D-N.Y., one of several sponsors of the bill. "We are finally at a place where we are debating how, not if."

Meanwhile, several key Republicans said the bill does not do enough to ensure the safety and effectiveness of highly complex biologic drugs.

Wyoming Sen. Mike Enzi, the senior Republican on the Senate Health, Education, Labor, and Pensions Committee, said if traditional drugs are as complex as a house, biologics were more akin to "a skyscraper."

"One girder out of place could cause the entire structure to fall," he said.

1 | 2

WebMD Video: Now Playing

Click here to wach video: Dirty Truth About Hand Washing

Which sex is the worst about washing up? Why is it so important? We’ve got the dirty truth on how and when to wash your hands.

Click here to watch video: Dirty Truth About Hand Washing